KRAS Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

KRAS Tests (In Vitro Diagnostics)-Global Market Analysis and Forecast Model

Global KRAS Tests (In Vitro Diagnostics) Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. Kirsten rat sarcoma (KRAS) is a downstream signaling molecule in the EGFR cellular pathway with roles in cell growth and proliferation.

It is commonly mutated in both CRC (39%) and NSCLC (25%) with the most frequent mutations in codons 12 and 13 causing over-activation of KRAS, which results in excessive cellular proliferation and tumor growth. There are no clinically approved therapies that target KRAS. However, its mutational status serves as an indication for response to approved anti-EGFR receptor antibodies in CRC and Tyrosine Kinase Inhibitors (TKIs) in NSCLC. Patients that have mutations in KRAS will not benefit from these anti-EGFR therapies.

Therefore, major organizations such as the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and others throughout Asia suggest that all late-stage metastatic CRC (stage IV) patients be tested for KRAS mutations when EGFR therapy is considered. However, such a strong consensus has not yet been reached for KRAS testing in late stages of NSCLC.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market Model

Currently marketed KRAS Tests and evolving competitive landscape-

– Insightful review of the key industry trends.

– Annualized total KRAS Tests market revenue by segment and market outlooks from 2015-2028.

– Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights-

– Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.

– SWOT analysis for the market.

– Competitive dynamics insights and trends provided for the overall market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

– Country specific overview of the healthcare system.

– Country specific reimbursement policies.

– Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd (Roche Diagnostics International Ltd), Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Agena Bioscience Inc, BML Inc, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Panagene Inc, EntroGen, Inc, Sysmex Corp, Biocartis Group NV and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for-

– CMO executives who must have deep understanding of the KRAS Tests marketplace to make strategic planning and investment decisions.

– Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

– Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

The model will enable you to-

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

– Develop business strategies by understanding the trends shaping and driving KRAS Tests market.

– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the KRAS Tests market in the future.

– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.

– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

– Track device sales in the global and country-specific KRAS Tests market from 2015-2028.

– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.